MTLS logo

MATERIALISE NV-ADR

MTLSNASDAQ
πŸ† #2964 by market capUS Equity
$661.69β–² $57.17 (+8.64%)
Simulated price
πŸ””
Track MTLS
Get earnings, price moves & breaking news on Telegram
Track
24hβ–² 8.6%
7dβ€”
14dβ€”
30dβ€”
ytdβ€”
1yβ€”
🏦Market Cap
$506M
Small Cap
πŸ“ˆRevenue Growth (YoY)
-1.2%
Declining
πŸ“ŠGross Margin
56.4%
Healthy
πŸ’΅FCF Margin
4.8%
Moderate
βš–οΈP/S Ratio
1.7x
Cheap
Otter Score
68
Fair
No chart data available for MTLS.

Trading Snapshot

Day Range
$659.53 – $669.47
52-Week Range
β€”
Volume
$2.00B
Avg Volume
$2.10B
Shares Outstanding
59.1M
Next Earnings
Nov 12, 2026

Fundamentals Snapshot

Annual Revenue
$257M
Last Q Revenue
$71M
P/E Ratio
98.5
P/S Ratio
1.7x
EPS (TTM)
β€”
Dividend Yield
β€”
Dilution (1yr)
βˆ’0.1%

Why Investors Own MTLS

  • βœ“High-growth profile β€” revenue up +45.0% YoY with expanding US Equity exposure.
  • βœ“Healthy economics β€” 60% gross margin and 18% free-cash-flow margin.
  • βœ“New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

MTLS logo

MATERIALISE NV-ADR

MTLS
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$257Mβ–Ό βˆ’3.6% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
57.1%β–² +1.1% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$5Mβ–Ό βˆ’47.6% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$9Mβ–² +79.9% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
59.1Mβ–Ό βˆ’0.1% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$68Mβ–² +$7M YoY
StockOtter Β· stockotter.space

About MATERIALISE NV-ADR

Materialise N.V. (MTLS), founded in 1990 and headquartered in Leuven, Belgium, is a global leader in additive manufacturing and medical technology. The company offers specialized software and comprehensive 3D printing services across the Americas, Europe, Africa, and Asia-Pacific regions. Its operations are divided into three core segments: 1. Materialise Software: This division develops sophisticated software solutions designed to empower and optimize the functionality of 3D printers and overall 3D printing workflows. Their software acts as a vital bridge, connecting various types of 3D printers with different software applications and data capture technologies, such as computer-aided design/manufacturing suites and 3D scanners. This segment serves a diverse clientele, including manufacturers of 3D printing equipment, production companies, and contract manufacturers in industries like automotive, aerospace, consumer goods, and hearing aids, as well as 3D printing service bureaus. Sales are conducted through their dedicated sales force, online platform, and a network of third-party distributors. 2. Materialise Medical: Focused on healthcare, this segment provides medical software that facilitates advanced medical-image-based analysis and engineering. This capability supports the personalized design of surgical devices and implants tailored to individual patients. Its customer base includes medical device companies, hospitals, universities, research institutions, and industrial firms, with sales handled by a direct sales team, their website, and through partnerships with picture archiving and communication system (PACS) providers. 3. Materialise Manufacturing: This segment delivers end-to-end 3D printing services. It encompasses design and engineering support, rapid prototyping, and the additive manufacturing of final production parts for a broad spectrum of industrial and commercial clients. Materialise N.V. also maintains significant collaboration agreements with several prominent companies in the medical field, including Zimmer Biomet Holdings, Inc.; Encore Medical, L.P.; DePuy Synthes Companies of Johnson & Johnson; Limacorporate Spa; Mathys AG; Corin Ltd; Medtronic Inc.; and Abbott Laboratories Inc.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Fair
68/100

Analyst Price Target

β“˜
Average Target
$683.45
β–² +3.3% Upside
High Target$838.45
Low Target$636.52
Based on 41 analysts

Latest News & Updates